14
Participants
Start Date
December 17, 2012
Primary Completion Date
April 7, 2016
Study Completion Date
August 30, 2016
Lenalidomide
"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
Rituximab
"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
University of California, San Francisco, San Francisco
Collaborators (2)
Celgene
INDUSTRY
Genentech, Inc.
INDUSTRY
James Rubenstein
OTHER